{"id":"W4231121000","doi":"10.1200/jco.2019.37.15_suppl.tps4155","title":"Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Clinical endpoint; Oncology; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001639958,0.002302235,0.003690498,0.0004670777,0.0004589532,0.00150458,0.001150449,0.001872471,0.006411702],"category_scores_gemma":[0.001604899,0.0008955717,0.002500288,0.0005645278,0.001221559,0.002281251,0.0005348863,0.004169149,0.001287348],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001262831,"about_ca_system_score_gemma":0.001633143,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001103808,"about_ca_topic_score_gemma":0.00336544,"domain_scores_codex":[0.9994532,0.0002839793,0.00002842287,0.00009592836,0.00004287998,0.00009543999],"domain_scores_gemma":[0.9992571,0.0001286584,0.0002026903,0.00005716407,0.00004769114,0.0003065639],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9661198,0.006368283,0.0008725284,0.0007929383,0.001072829,0.00009871976,0.00008188598,0.0009034562,0.003120288,0.0001998521,0.002203163,0.0181662],"study_design_scores_gemma":[0.9356195,0.0607825,0.001272945,0.00002701451,0.0002954042,0.00009644061,0.00002827082,0.0005247372,0.0002637497,0.0002269817,0.0008428375,0.00001959529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804679,0.006657542,0.0006950658,0.001506781,0.0007795325,0.00505152,0.001865906,0.0002288742,0.002746942],"genre_scores_gemma":[0.978071,0.004101756,0.002351354,0.002129429,0.0004081542,0.005557764,0.002663074,0.00007283261,0.004644518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006411702,"threshold_uncertainty_score":0.02144927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1155206016949348,"score_gpt":0.4541062629948091,"score_spread":0.3385856612998743,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}